BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Rhea-AI Summary

BioMarin Pharmaceutical (NASDAQ: BMRN) has scheduled its fourth quarter and full-year 2024 financial results conference call and webcast for Wednesday, February 19, 2025, at 4:30 p.m. ET. The event will be hosted by Alexander Hardy, President and Chief Executive Officer, who will discuss financial results and provide a general business update.

Participants can join via phone using U.S./Canada dial-in (800-715-9871) or International dial-in (646-307-1963) with Conference ID 1878833. A live audio webcast will be available through BioMarin's investor website. A replay will be accessible for one week following the call, with U.S./Canada replay number (800-770-2030) and International replay number (609-800-9909), Playback ID 1878833.

SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 1878833

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1878833 

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com. 

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-and-webcast-on-wednesday-february-19-2025-at-430pm-et-302368081.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) release its Q4 and full-year 2024 earnings?

BioMarin will release its Q4 and full-year 2024 earnings on Wednesday, February 19, 2025, at 4:30 p.m. ET.

How can investors access BioMarin's (BMRN) Q4 2024 earnings call?

Investors can access the call via phone (U.S./Canada: 800-715-9871, International: 646-307-1963, ID: 1878833) or through a live webcast on BioMarin's investor website.

Will there be a replay available for BioMarin's (BMRN) Q4 2024 earnings call?

Yes, a replay will be available for one week after the call using U.S./Canada number (800-770-2030) or International number (609-800-9909) with Playback ID 1878833.

Who will host BioMarin's (BMRN) Q4 2024 earnings call?

Alexander Hardy, President and Chief Executive Officer of BioMarin, will host the earnings call and webcast.